Welcome to our dedicated page for Stereotaxis Ord SEC filings (Ticker: STXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating FDA milestones, patent disclosures, and segment revenue buried inside Stereotaxis’s dense SEC documents can feel like performing surgery without a scope. Each report blends medical-device regulation, robotics engineering, and reimbursement detail—material that sends many investors straight to the glossary.
Stock Titan solves that problem. Our platform delivers AI-powered summaries that turn a 300-page filing into a five-minute brief. Whether you need the Stereotaxis quarterly earnings report 10-Q filing for trend analysis or want Stereotaxis insider trading Form 4 transactions on your screen the moment they post, we provide real-time EDGAR updates, plain-English explanations, and side-by-side financial tables. Use our filters to jump directly to risk factors about FDA clearance, compare R&D spend across quarters, or spot warranty reserve movements without scrolling.
All major forms are covered: the Stereotaxis annual report 10-K simplified highlights robotics adoption rates; Stereotaxis proxy statement executive compensation details pay tied to new system installs; Stereotaxis 8-K material events explained flags unexpected trial results; and Stereotaxis Form 4 insider transactions real-time tracks when executives accumulate shares. Want deeper context? Our AI links numbers to narrative—think understanding Stereotaxis SEC documents with AI rather than leafing through exhibits. Practical use cases include monitoring pipeline progress before material announcements, benchmarking hospital install base growth, and catching cash-flow pivots early through Stereotaxis earnings report filing analysis.
Stereotaxis, Inc. reported stronger top-line results for the quarter ended June 30, 2025, with total revenue of $8.8 million, up from $4.5 million a year earlier, and $16.3 million for the six months versus $11.4 million in 2024. Growth was driven by higher systems sales ($3.0 million in Q2 2025 versus $0.24 million) and increased disposables, service and accessories revenue. Gross margin improved to $4.6 million in the quarter from $3.3 million a year ago, and operating loss narrowed to $4.0 million from $6.0 million in the prior-year quarter.
Despite improved operating performance, the company remains unprofitable with a six-month net loss of $9.6 million and a cumulative deficit of approximately $571.4 million. Cash and cash equivalents were $6.97 million at June 30, 2025, and operating cash used was $5.5 million for the six months. The company completed an earlier acquisition of Access Point Technologies (APT), recognized related intangible assets and goodwill, recorded a $0.5 million contingent consideration revaluation charge, and disclosed a July 2025 registered offering with initial gross proceeds of $8.5 million and $4.0 million expected at a later closing.
FAQ
What is the current stock price of Stereotaxis Ord (STXS)?
What is the market cap of Stereotaxis Ord (STXS)?
